权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

心脏病患者焦虑的运动和药物治疗

基本信息

批准号：
9113594
负责人：
James A Blumenthal
金额：
$ 78.02万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-01 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9113594
关键词：
Accounting Acute Coronary Event Adult Adverse effects Adverse event Affect American American Heart Association Anti-Anxiety Agents Anxiety Anxiety Disorders Autonomic nervous system Biological Markers Blood Blood Vessels Cardiac Cardiac rehabilitation Cardiovascular system Cause of Death Characteristics Cholesterol Chronic Clinic Clinical Clinical Research Clinical Trials Design Clinical assessments Coronary heart disease Data Diagnosis Effectiveness Escitalopram Event Exercise Health Health Care Costs Heart Hospitalization Hypertension Inflammation Intervention Lexapro Literature Maintenance Major Depressive Disorder Measures Mediating Medical Mental Depression Monitor Morbidity - disease rate Myocardial Odds Ratio Outcome Outpatients Participant Patients Pharmaceutical Preparations Pharmacotherapy Physiological Placebos Population Prevalence Prognostic Factor Psychosocial Factor Quality of life Randomized Randomized Clinical Trials Recommendation Regulation Reporting Research Risk Risk Factors Selective Serotonin Reuptake Inhibitor Severity of illness Smoking Therapeutic Time Training United States Woman Work anxiety symptoms anxiety treatment anxious base cardiovascular risk factor clinically significant cost depressive symptoms design exercise training follow-up heart disease risk improved improved outcome men mortality outcome forecast prognostic significance psychologic reduce symptoms vascular endothelial dysfunction

项目摘要

DESCRIPTION (provided by applicant): Coronary heart disease (CHD) is the leading cause of death in the United States, affecting 600,000 Americans each year. The term "cardiovascular vulnerable patient" has been used to describe patients susceptible to acute coronary events based upon plaque, blood, or myocardial characteristics. Recent evidence has suggested that anxiety, which is common in CHD patients, may be a significant and independent prognostic factor that also increases cardiovascular vulnerability. This evidence has provided a rationale for reducing anxiety in cardiac patients. Anxiolytic medications, especially selective serotonin reuptake inhibitors (SSRIs), may be effective in this regard, although the value of these medications in reducing anxiety has not been widely studied in cardiac patients and their value in improving clinical outcomes is not known. Exercise also may be effective in reducing anxiety, although the therapeutic potential of exercise has remained unfulfilled due to a paucity of data from well-designed clinical studies. The study proposed in this application will (a) evaluate the effectiveness of exercise training and anxiolytic medication in reducing anxiety in vulnerable cardiac patients; (b) examine changes in intermediate endpoints, including measures of autonomic nervous system dysregulation, vascular endothelial dysfunction, and chronic inflammation, which also serve as physiologic markers of vulnerability to adverse cardiac events; (c) follow participants for up to 4 years to assess clinical events including fatal and non fatal cardiac events, hospitalizations, and medical costs; and (d) explore possible mechanisms by which the interventions improve outcomes. One hundred fifty men and women with CHD and an anxiety disorder or elevated symptoms of anxiety will be randomly assigned to Exercise, Medication (escitalopram), or Placebo. Before and after 3 months of treatment, patients will undergo clinical assessments of anxiety and measures of autonomic nervous system regulation, vascular endothelial function, and inflammation. A six month follow-up will assess maintenance of psychological benefit and clinical outcomes will be monitored for up to 4 years. The data generated from this study will have important clinical significance by determining the extent to which exercise and medication may reduce anxiety, improve intermediate markers of CHD risk, and improve medical outcomes including clinical events and CHD-related hospitalizations.